- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- Insurance rollout shows pharmacies and NACDS in action
- Novartis names new head of sales U.S.
- CVS/pharmacy's new system to help patients compare Medicare Part D plans
- CMS Medicare analysis found mail order more expensive than community pharmacy across 21 plans
BASKING RIDGE, N.J. — A Mylan subsidiary has settled a lawsuit brought on by the Department of Justice four years ago.
Dey Pharma — which was involved in the suit prior to begin acquired by Mylan from Merck KGaA in 2007 — said that it agreed to pay $280 million to the DoJ in exchange for a release of claims, which dealt with Medicare and Medicaid reimbursements paid by the federal government to pharmacists and other healthcare providers. Dey added that Merck KGaA is responsible for paying the full amount of this settlement, as well as all costs and other expenses associated with pending and future-related lawsuits.
The settlement agreement confirmed that the resolution of the case does not constitute an admission, finding or evidence of fault, liability or wrongdoing by Dey, the drug maker said.